Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

Improved Dose-Response Relationship of (+)-Discodermolide-Taxol Hybrid Congeners.

Nadaradjane C, Yang CH, Rodriguez-Gabin A, Ye K, Sugasawa K, Atasoylu O, Smith AB 3rd, Horwitz SB, McDaid HM.

J Nat Prod. 2018 Mar 23;81(3):607-615. doi: 10.1021/acs.jnatprod.8b00111. Epub 2018 Mar 9.

2.

Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of β-Tubulin and the Multidrug Resistance Associated P-Glycoprotein.

Yang CH, Wang C, Ojima I, Horwitz SB.

J Nat Prod. 2018 Mar 23;81(3):600-606. doi: 10.1021/acs.jnatprod.7b01047. Epub 2018 Mar 8.

PMID:
29517223
3.

Expression of βV-Tubulin in Secretory Cells of the Fallopian Tube Epithelium Marks Cellular Atypia.

Mathew D, Wang Y, Van Arsdale A, Horwitz SB, McDaid H.

Int J Gynecol Cancer. 2018 Feb;28(2):363-370. doi: 10.1097/IGC.0000000000001160.

4.

Taxol®: The First Microtubule Stabilizing Agent.

Yang CH, Horwitz SB.

Int J Mol Sci. 2017 Aug 9;18(8). pii: E1733. doi: 10.3390/ijms18081733. Review.

5.

Structural Basis of Microtubule Stabilization by Discodermolide.

Prota AE, Bargsten K, Redondo-Horcajo M, Smith AB 3rd, Yang CH, McDaid HM, Paterson I, Horwitz SB, Fernando Díaz J, Steinmetz MO.

Chembiochem. 2017 May 18;18(10):905-909. doi: 10.1002/cbic.201600696. Epub 2017 Mar 27.

6.

2-(m-Azidobenzoyl)taxol binds differentially to distinct β-tubulin isotypes.

Yang CH, Yap EH, Xiao H, Fiser A, Horwitz SB.

Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):11294-11299. Epub 2016 Sep 20.

7.

Termination of Protofilament Elongation by Eribulin Induces Lattice Defects that Promote Microtubule Catastrophes.

Doodhi H, Prota AE, Rodríguez-García R, Xiao H, Custar DW, Bargsten K, Katrukha EA, Hilbert M, Hua S, Jiang K, Grigoriev I, Yang CH, Cox D, Horwitz SB, Kapitein LC, Akhmanova A, Steinmetz MO.

Curr Biol. 2016 Jul 11;26(13):1713-1721. doi: 10.1016/j.cub.2016.04.053. Epub 2016 Jun 16.

8.

Germline mutations of the DNA repair pathways in uterine serous carcinoma.

Frimer M, Levano KS, Rodriguez-Gabin A, Wang Y, Goldberg GL, Horwitz SB, Hou JY.

Gynecol Oncol. 2016 Apr;141(1):101-7. doi: 10.1016/j.ygyno.2015.12.034.

PMID:
27016235
9.

Correction: Exploiting MEK Inhibitor-Mediated Activation of ERα for Therapeutic Intervention in ER-Positive Ovarian Carcinoma.

Hou JY, Rodriguez-Gabin A, Samaraweera L, Hazan R, Goldberg GL, Horwitz SB, McDaid HM.

PLoS One. 2016 Mar 11;11(3):e0151750. doi: 10.1371/journal.pone.0151750. eCollection 2016. No abstract available.

10.

A Symposium in Honor of Richard G. Powell, a Long-Time Associate Editor of the Journal of Natural Products.

Horwitz SB, Kinghorn AD.

J Nat Prod. 2015 Oct 23;78(10):2317-8. doi: 10.1021/acs.jnatprod.5b00856. Epub 2015 Oct 1. No abstract available.

PMID:
26426905
11.

TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.

Seagle BL, Yang CP, Eng KH, Dandapani M, Odunsi-Akanji O, Goldberg GL, Odunsi K, Horwitz SB, Shahabi S.

Gynecol Oncol. 2015 Jul;138(1):159-64. doi: 10.1016/j.ygyno.2015.04.039. Epub 2015 May 6.

12.

A conversation with Susan Band Horwitz.

Horwitz SB, Goldman ID.

Annu Rev Pharmacol Toxicol. 2015;55:1-9. doi: 10.1146/annurev-pharmtox-010814-124519.

PMID:
25562642
13.

Eribulin disrupts EB1-microtubule plus-tip complex formation.

O'Rourke B, Yang CP, Sharp D, Horwitz SB.

Cell Cycle. 2014;13(20):3218-21. doi: 10.4161/15384101.2014.950143.

14.

Nature as a remarkable chemist: a personal story of the discovery and development of Taxol.

Wani MC, Horwitz SB.

Anticancer Drugs. 2014 May;25(5):482-7. doi: 10.1097/CAD.0000000000000063. Review.

15.

Proteomics of cancer cell lines resistant to microtubule-stabilizing agents.

Albrethsen J, Angeletti RH, Horwitz SB, Yang CP.

Mol Cancer Ther. 2014 Jan;13(1):260-9. doi: 10.1158/1535-7163.MCT-13-0471. Epub 2013 Nov 19.

16.

Heterozygous disruption of renal outer medullary potassium channel in rats is associated with reduced blood pressure.

Zhou X, Zhang Z, Shin MK, Horwitz SB, Levorse JM, Zhu L, Sharif-Rodriguez W, Streltsov DY, Dajee M, Hernandez M, Pan Y, Urosevic-Price O, Wang L, Forrest G, Szeto D, Zhu Y, Cui Y, Michael B, Balogh LA, Welling PA, Wade JB, Roy S, Sullivan KA.

Hypertension. 2013 Aug;62(2):288-94. doi: 10.1161/HYPERTENSIONAHA.111.01051. Epub 2013 Jun 10.

PMID:
23753405
17.

Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.

Hou JY, Rodriguez-Gabin A, Samaraweera L, Hazan R, Goldberg GL, Horwitz SB, McDaid HM.

PLoS One. 2013;8(2):e54103. doi: 10.1371/journal.pone.0054103. Epub 2013 Feb 4. Erratum in: PLoS One. 2016;11(3):e0151750. Samaweera, Leleesha [corrected to Samaraweera, Leleesha].

18.

High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer.

Wang Y, Sparano JA, Fineberg S, Stead L, Sunkara J, Horwitz SB, McDaid HM.

Clin Breast Cancer. 2013 Apr;13(2):103-8. doi: 10.1016/j.clbc.2012.11.003. Epub 2012 Dec 6.

19.

Synthesis and Biological Evaluation of Novel 3'-Difluorovinyl Taxoids.

Kuznetsova L, Sun L, Chen J, Zhao X, Seitz J, Das M, Li Y, Veith JM, Pera P, Bernacki RJ, Xia S, Horwitz SB, Ojima I.

J Fluor Chem. 2012 Nov 1;143:177-188. Epub 2012 Jul 28.

20.

Characterization of a human βV-tubulin antibody and expression of this isotype in normal and malignant human tissue.

Chao SK, Wang Y, Verdier-Pinard P, Yang CP, Liu L, Rodriguez-Gabin A, McDaid HM, Horwitz SB.

Cytoskeleton (Hoboken). 2012 Aug;69(8):566-76. doi: 10.1002/cm.21043. Epub 2012 Jul 2.

21.

Structural evidence for cooperative microtubule stabilization by Taxol and the endogenous dynamics regulator MAP4.

Xiao H, Wang H, Zhang X, Tu Z, Bulinski C, Khrapunovich-Baine M, Hogue Angeletti R, Horwitz SB.

ACS Chem Biol. 2012 Apr 20;7(4):744-52. doi: 10.1021/cb200403x. Epub 2012 Feb 6.

22.

Design and synthesis of (+)-discodermolide-paclitaxel hybrids leading to enhanced biological activity.

Smith AB, Sugasawa K, Atasoylu O, Yang CP, Horwitz SB.

J Med Chem. 2011 Sep 22;54(18):6319-27. doi: 10.1021/jm200692n. Epub 2011 Aug 26.

23.

Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence.

Chao SK, Horwitz SB, McDaid HM.

Oncotarget. 2011 Jan-Feb;2(1-2):89-98.

24.

Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation.

Khrapunovich-Baine M, Menon V, Yang CP, Northcote PT, Miller JH, Angeletti RH, Fiser A, Horwitz SB, Xiao H.

J Biol Chem. 2011 Apr 1;286(13):11765-78. doi: 10.1074/jbc.M110.162214. Epub 2011 Jan 18.

25.

Resistance to discodermolide, a microtubule-stabilizing agent and senescence inducer, is 4E-BP1-dependent.

Chao SK, Lin J, Brouwer-Visser J, Smith AB 3rd, Horwitz SB, McDaid HM.

Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):391-6. doi: 10.1073/pnas.1016962108. Epub 2010 Dec 20.

26.

Epothilone B enhances surface EpCAM expression in ovarian cancer Hey cells.

Shahabi S, Yang CP, Goldberg GL, Horwitz SB.

Gynecol Oncol. 2010 Nov;119(2):345-50. doi: 10.1016/j.ygyno.2010.07.005. Epub 2010 Aug 2.

27.

Methods in tubulin proteomics.

Miller LM, Xiao H, Burd B, Horwitz SB, Angeletti RH, Verdier-Pinard P.

Methods Cell Biol. 2010;95:105-26. doi: 10.1016/S0091-679X(10)95007-3. Review.

28.

Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.

Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER, Goldberg GL, Smith HO, Horwitz SB.

Clin Cancer Res. 2010 Jun 1;16(11):2999-3010. doi: 10.1158/1078-0432.CCR-09-3233. Epub 2010 Apr 19.

29.

The interaction between mitotic checkpoint proteins, CENP-E and BubR1, is diminished in epothilone B-resistant A549 cells.

Yang CP, Liu L, Ikui AE, Horwitz SB.

Cell Cycle. 2010 Mar 15;9(6):1207-13. Epub 2010 Mar 15.

PMID:
20237434
30.

Distinct pose of discodermolide in taxol binding pocket drives a complementary mode of microtubule stabilization.

Khrapunovich-Baine M, Menon V, Verdier-Pinard P, Smith AB 3rd, Angeletti RH, Fiser A, Horwitz SB, Xiao H.

Biochemistry. 2009 Dec 15;48(49):11664-77. doi: 10.1021/bi901351q.

31.

Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma.

Huang GS, Arend RC, Li M, Gunter MJ, Chiu LG, Horwitz SB, Goldberg GL.

Am J Obstet Gynecol. 2009 Apr;200(4):457.e1-5. doi: 10.1016/j.ajog.2008.12.012. Epub 2009 Feb 6.

32.

Design, synthesis, and biological evaluation of novel C14-C3'BzN-linked macrocyclic taxoids.

Sun L, Geng X, Geney R, Li Y, Simmerling C, Li Z, Lauher JW, Xia S, Horwitz SB, Veith JM, Pera P, Bernacki RJ, Ojima I.

J Org Chem. 2008 Dec 19;73(24):9584-93. doi: 10.1021/jo801713q.

33.

Tubulin proteomics: towards breaking the code.

Verdier-Pinard P, Pasquier E, Xiao H, Burd B, Villard C, Lafitte D, Miller LM, Angeletti RH, Horwitz SB, Braguer D.

Anal Biochem. 2009 Jan 15;384(2):197-206. doi: 10.1016/j.ab.2008.09.020. Epub 2008 Sep 18. Review. No abstract available.

34.

Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.

Jordan MA, Horwitz SB, Lobert S, Correia JJ.

Semin Oncol. 2008 Jun;35(3 Suppl 3):S6-S12. doi: 10.1053/j.seminoncol.2008.01.009. Review.

PMID:
18538179
35.

Introduction. The novel microtubule inhibitor vinflunine.

Horwitz SB.

Semin Oncol. 2008 Jun;35(3 Suppl 3):S1-2. doi: 10.1053/j.seminoncol.2008.01.005. No abstract available.

PMID:
18538173
36.

Stathmin/Op18 is a novel mediator of vinblastine activity.

Devred F, Tsvetkov PO, Barbier P, Allegro D, Horwitz SB, Makarov AA, Peyrot V.

FEBS Lett. 2008 Jul 23;582(17):2484-8. doi: 10.1016/j.febslet.2008.06.035. Epub 2008 Jun 25.

37.

Increased levels of a unique post-translationally modified betaIVb-tubulin isotype in liver cancer.

Miller LM, Menthena A, Chatterjee C, Verdier-Pinard P, Novikoff PM, Horwitz SB, Angeletti RH.

Biochemistry. 2008 Jul 15;47(28):7572-82. doi: 10.1021/bi8005225. Epub 2008 Jun 21.

38.

Design, synthesis, and biological evaluation of new-generation taxoids.

Ojima I, Chen J, Sun L, Borella CP, Wang T, Miller ML, Lin S, Geng X, Kuznetsova L, Qu C, Gallager D, Zhao X, Zanardi I, Xia S, Horwitz SB, Mallen-St Clair J, Guerriero JL, Bar-Sagi D, Veith JM, Pera P, Bernacki RJ.

J Med Chem. 2008 Jun 12;51(11):3203-21. doi: 10.1021/jm800086e. Epub 2008 May 9.

39.

The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development.

Goel S, Cohen M, Cömezoglu SN, Perrin L, André F, Jayabalan D, Iacono L, Comprelli A, Ly VT, Zhang D, Xu C, Humphreys WG, McDaid H, Goldberg G, Horwitz SB, Mani S.

Clin Cancer Res. 2008 May 1;14(9):2701-9. doi: 10.1158/1078-0432.CCR-07-4151.

40.

Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression.

Legrier ME, Yang CP, Yan HG, Lopez-Barcons L, Keller SM, Pérez-Soler R, Horwitz SB, McDaid HM.

Cancer Res. 2007 Dec 1;67(23):11300-8.

41.

Wild-type class I beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation.

Wiesen KM, Xia S, Yang CP, Horwitz SB.

Cancer Lett. 2007 Nov 18;257(2):227-35. Epub 2007 Sep 14.

PMID:
17869412
42.

Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone.

Mani S, McDaid HM, Grossman A, Muggia F, Goel S, Griffin T, Colevas D, Horwitz SB, Egorin MJ.

Ann Oncol. 2007 Jan;18(1):190-5. Epub 2006 Oct 3.

PMID:
17018704
43.

A photoaffinity analogue of discodermolide specifically labels a peptide in beta-tubulin.

Xia S, Kenesky CS, Rucker PV, Smith AB 3rd, Orr GA, Horwitz SB.

Biochemistry. 2006 Oct 3;45(39):11762-75.

PMID:
17002277
44.

Insights into the mechanism of microtubule stabilization by Taxol.

Xiao H, Verdier-Pinard P, Fernandez-Fuentes N, Burd B, Angeletti R, Fiser A, Horwitz SB, Orr GA.

Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10166-10173. doi: 10.1073/pnas.0603704103. Epub 2006 Jun 26.

45.

Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice.

Huang GS, Lopez-Barcons L, Freeze BS, Smith AB 3rd, Goldberg GL, Horwitz SB, McDaid HM.

Clin Cancer Res. 2006 Jan 1;12(1):298-304.

46.

Detection of human betaV-tubulin expression in epithelial cancer cell lines by tubulin proteomics.

Verdier-Pinard P, Shahabi S, Wang F, Burd B, Xiao H, Goldberg GL, Orr GA, Horwitz SB.

Biochemistry. 2005 Dec 6;44(48):15858-70.

PMID:
16313188
47.

Design, synthesis, and biological evaluation of potent discodermolide fluorescent and photoaffinity molecular probes.

Smith AB 3rd, Rucker PV, Brouard I, Freeze BS, Xia S, Horwitz SB.

Org Lett. 2005 Nov 10;7(23):5199-202.

PMID:
16268537
48.

Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents.

Mani S, Huang H, Sundarababu S, Liu W, Kalpana G, Smith AB, Horwitz SB.

Clin Cancer Res. 2005 Sep 1;11(17):6359-69.

49.
50.

A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence.

Yang CP, Verdier-Pinard P, Wang F, Lippaine-Horvath E, He L, Li D, Höfle G, Ojima I, Orr GA, Horwitz SB.

Mol Cancer Ther. 2005 Jun;4(6):987-95.

Supplemental Content

Loading ...
Support Center